The Journal of Urology
Volume 180, Issue 2 , Pages 433-434 , August 2008

Renal Masses—To Treat or Not to Treat? If That is the Question are Contemporary Biomarkers the Answer?

References 

  1. Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn't. BMJ. 1996;312::71
  2. Kunkle DA, Egleston BL, Uzzo RG. Excise, ablate or observe: the small renal mass dilemma–a meta-analysis and review. J Urol. 2008;179:1227
  3. Kunkle DA, Crispen PL, Chen DYT, Greenberg RE, Uzzo RG. Enhancing renal masses with zero net growth during active surveillance. J Urol. 2007;177:849
  4. Chawla SN, Crispen PL, Hanlon AL, Greenberg RE, Chen DY, Uzzo RG. The natural history of observed enhancing renal masses: meta-analysis and review of the world literature. J Urol. 2006;175:425
  5. Crispen PL, Viterbo R, Fox EB, Greenberg RE, Chen DYT, Uzzo RG. Delayed intervention of sporadic renal masses undergoing active surveillance. Cancer. 2008;112:1051
  6. Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001;345:1655
  7. Crispen PL, Boorjian SA, Lohse CM, Leibovich BC, Kwon ED. Predicting disease progression after nephrectomy for localized renal cell carcinoma: the utility of prognostic models and molecular biomarkers. Cancer. 2008;Epub ahead of print

PII: S0022-5347(08)01204-4

doi: 10.1016/j.juro.2008.04.124

The Journal of Urology
Volume 180, Issue 2 , Pages 433-434 , August 2008

Article Tools